Related Experiment Videos
[Therapeutic options for improvement of myocardial perfusion in coronary atherosclerosis]
1Medizinische Klinik IV, Abteilung Kardiologie, Johann-Wolfgang-Goethe-Universität Frankfurt. schaechinger@em.uni-frankfurt.de
Insights
Improving endothelial function through therapies like ACE-inhibitors or lipid-lowering drugs enhances myocardial perfusion in coronary artery disease patients. These treatments may improve prognosis, even in early stages of vascular disease.
Area of Science:
- Cardiovascular Medicine
- Vascular Biology
- Pharmacology
Context:
- Coronary artery disease involves atherosclerotic changes and impaired vasomotor control, affecting myocardial oxygen supply.
- Endothelial dysfunction is central to coronary vessel alterations in early atherosclerosis and risk factors.
- Nitric oxide (NO) and superoxide radical (O2-) balance, influenced by angiotensin II, governs vasomotor tone and proliferation.
Purpose:
- To explore therapeutic strategies that enhance nitric oxide (NO) bioavailability and improve endothelial function in coronary artery disease.
- To investigate treatments that ameliorate endothelium-dependent vasodilation and reduce oxidative stress in the vascular wall.
- To assess the potential of therapies targeting endothelial dysfunction for improving myocardial perfusion and patient prognosis.
Summary:
- Therapies like ACE-inhibitors, physical exercise, estrogens, L-arginine, antioxidants, and lipid-lowering drugs can improve endothelial vasodilator capacity.
- Reducing oxidative stress and enhancing NO production are key aims for therapeutic interventions.
- Endothelin-antagonists and angiotensin II receptor-blockers show promise but require further validation.
Impact:
- Improving endothelial function can enhance myocardial perfusion, offering symptomatic relief even in patients with minimal coronary atherosclerosis.
- Many therapies that ameliorate endothelial dysfunction also demonstrate improved patient prognosis.
- Further research is needed to determine if endothelial dysfunction alone warrants long-term prognostic therapy.
Abstract:
The combination of morphological atherosclerotic alterations of coronary vessels and disturbance of coronary vasomotor control of epicardial and resistance vessels determines the amount of myocardial oxygen supply. The endothelium plays a crucial role for functional alterations of the coronary vessels in patients with early atherosclerosis or risk factors for coronary artery disease. A therapy which aims to ameliorate endothelium-dependent vasodilator capacity improves myocardial perfusion in patients with coronary artery disease. Thereby, even in patients with angiographically normal or minimally diseased coronary vessels who develop myocardial ischemia due to microvascular disease, symptomatic improvement might be achieved. Control of coronary vasomotor tone and proliferation processes within the vessel wall are both determined by the redox equilibrium of nitric oxide (NO) and superoxide radicals (O2-), induced by angiotensin II. Thus, vasomotor control and vessel wall proliferation is closely related to each other. Aim of a therapeutic intervention to enhance NO bioactivity is either to increase NO production in the endothelium or to decrease O2- production, which rapidly inactivates NO. NO bioactivity can be ameliorated by ACE-inhibitors, increase of shear stress on the endothelium by physical exercise, estrogens or L-arginine. For these therapies clinically an improvement of endothelial vasodilator function could be shown. In addition, improvement of endothelial vasodilator function can be achieved by a treatment which reduced oxidative stress in the vascular wall such as antioxidants and, especially, lipid lowering drugs. Endothelin-antagonists and angiotensin II receptor-blockers are promising to improve endothelial dysfunction. However, these therapies have to be validated. Most therapy strategies, which have shown to ameliorate endothelial dysfunction, are also able to improve prognosis of the patients. Whether endothelial dysfunction alone--without evidence of overt coronary atherosclerosis--is sufficient to justify a long-term therapy to improve prognosis, still has to be clarified.